TLSI (TriSalus Life Sciences) Tax Rate %: 0.26% (As of Mar. 2026)


TLSI TriSalus Life Sciences Inc TLSI
29 GF Score
Price $3.82
GF Value $4.31
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is TriSalus Life Sciences Tax Rate %?

TriSalus Life Sciences TLSI +3.80% 29 Tax Rate % is 0.26% as of Mar. 2026. GuruFocus rates TLSI with a GF Score™ of 29/100 and a GF Value™ of $4.31 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Tax Rate % is calculated as Tax Expense divided by its Pre-Tax Income. TriSalus Life Sciences's Tax Expense for the three months ended in Mar. 2026 was $0.00 Mil. TriSalus Life Sciences's Pre-Tax Income for the three months ended in Mar. 2026 was $1.54 Mil. Therefore, TriSalus Life Sciences's Tax Rate % for the quarter that ended in Mar. 2026 was 0.26%.

TriSalus Life Sciences Tax Rate % Related Terms

TriSalus Life Sciences Tax Rate % Historical Data

* Premium members only.

The historical data trend for TriSalus Life Sciences's Tax Rate % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TriSalus Life Sciences Tax Rate % Chart

TriSalus Life Sciences Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Tax Rate %
-0.01 -0.02 -0.02 -0.02 -0.02

TriSalus Life Sciences Quarterly Data
Dec21 Mar22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Tax Rate % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.05 0.04 -0.05 0.00 0.26
TLSI
29GF Score
TriSalus Life Sciences Inc TLSI
Tax Rate % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TriSalus Life Sciences Tax Rate % Calculation

Tax Rate % is the ratio of tax expense divided by pretax income, usually presented in percent.

TriSalus Life Sciences's Tax Rate % for the fiscal year that ended in Dec. 2025 is calculated as

Tax Rate %=Tax Expense (A: Dec. 2025 )/Pre-Tax Income (A: Dec. 2025 )
=0.007/-39.22
=-0.02 %

TriSalus Life Sciences's Tax Rate % for the quarter that ended in Mar. 2026 is calculated as

Tax Rate %=Tax Expense (Q: Mar. 2026 )/Pre-Tax Income (Q: Mar. 2026 )
=0.004/1.543
=0.26 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Tax Rate % →
What does a Tax Rate % of 0.26% mean?
TriSalus Life Sciences (TLSI) has a Tax Rate % of 0.26% as of Mar. 2026.
Is TriSalus Life Sciences' Tax Rate % too high?
TriSalus Life Sciences' current Tax Rate % is 0.26%. Overall, TriSalus Life Sciences has a GF Score™ of 29/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TriSalus Life Sciences' Tax Rate % compare to TMCI and LAB?
TriSalus Life Sciences' Tax Rate % of 0.26% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tax Rate % for a Medical Devices & Instruments company?
A good Tax Rate % depends on the Medical Devices & Instruments industry context. However, Tax Rate % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tax Rate % mean?
A high Tax Rate % can signal that a stock is expensive relative to its fundamentals. TriSalus Life Sciences's current Tax Rate % is 0.26%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TriSalus Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, TriSalus Life Sciences (TLSI) is currently considered Modestly Undervalued. The stock's GF Value™ is $4.31, compared to a current price of $3.82 — trading 11.4% below its estimated fair value. The current Tax Rate % is 0.26%. TriSalus Life Sciences' overall GF Score™ is 29/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tax Rate % calculated?
Tax Rate % is calculated from a company's financial statements. For TriSalus Life Sciences (TLSI), the current Tax Rate % is 0.26% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is TriSalus Life Sciences (TLSI) Overvalued in 2026?

Based on GuruFocus' analysis, TriSalus Life Sciences stock appears to be undervalued. The current stock price of $3.82 is trading 11.4% below its estimated GF Value™ of $4.31. GuruFocus considers TriSalus Life Sciences to be Modestly Undervalued.

Key valuation signals for TLSI:

  • Tax Rate %: 0.26%
  • GF Value™: $4.31 vs. price of $3.82 (11.4% below fair value)
  • GF Score™: 29/100 with 4 warning signs

No single metric tells the full story. See the TLSI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

TriSalus Life Sciences Business Description

Address 6272 W. 91st Avenue, Westminster, CO, USA, 80031
TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.
29GF Score

Get the complete analysis for TLSI

Tax Rate % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.82
Price
$4.31
GF Value